Other explanations for the discrepancy of ACE2 expression levels in β cells have also been discussed, such as low sample size, results based on non-COVID-19 pancreatic tissues [75,81,82,83,84], low detection sensitivity of employed methods [85,89], differences in gender and ethnic background [81,85,86], inconsistent methodology for sample preservation or preparation between studies [75], negative effects of rapid pancreas autolysis for receptor detection [82], and rapid data evaluation and fast publication turnover [75]. The gene discussed is ACE2; the disease is COVID-19.